Charles River Laboratories International Inc
NYSE:CRL
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
178.58
273.43
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Charles River Laboratories International Inc
Wall Street
Price Targets
CRL Price Targets Summary
Charles River Laboratories International Inc
According to Wall Street analysts, the average 1-year price target for
CRL
is 220.21 USD
with a low forecast of 172.71 USD and a high forecast of 272.17 USD.
CRL Last Price Targets
Charles River Laboratories International Inc
The latest public price target was made on Oct 15, 2024 by
Luke Sergott
from
Barclays
,
who expects
CRL
stock to
rise by 11%
over the next 12 months.
You can read more about this price target by viewing
the article on TheFly.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Luke Sergott
Barclays
|
205
USD
Upside 11% |
2 months ago
Oct 15, 2024
|
Charles River price target lowered to $205 from $210 at Barclays
TheFly
|
|
Jamie Clark
Redburn Partners
|
151
USD
Downside 19% |
2 months ago
Oct 14, 2024
|
Charles River initiated with a Sell at Redburn Atlantic
TheFly
|
Ann Hynes
Mizuho Securities
|
210
USD
Upside 13% |
3 months ago
Sep 17, 2024
|
Mizuho Reiterates Neutral Rating on Charles River Labs (CRL)
StreetInsider
|
Justin Bowers
Deutsche Bank
|
240
USD
Upside 29% |
4 months ago
Aug 8, 2024
|
Charles River price target lowered to $240 from $300 at Deutsche Bank
TheFly
|
Eric Coldwell
Robert W. Baird
|
239
USD
Upside 29% |
5 months ago
Jul 10, 2024
|
Charles River price target lowered to $239 from $271 at Baird
TheFly
|
|
Luke Sergott
Barclays
|
230
USD
Upside 24% |
5 months ago
Jun 28, 2024
|
Barclays Starts Charles River Labs (CRL) at Equalweight
StreetInsider
|
Matthew Sykes
Goldman Sachs
|
290
USD
Upside 56% |
6 months ago
Jun 6, 2024
|
Goldman Sachs Starts Charles River Labs (CRL) at Buy
StreetInsider
|
Elizabeth Anderson
Evercore ISI
|
265
USD
Upside 43% |
7 months ago
May 9, 2024
|
Charles River Labs (CRL) PT Lowered to $265 at Evercore ISI
StreetInsider
|
|
Elizabeth Anderson
Evercore ISI
|
300
USD
Upside 62% |
8 months ago
Apr 1, 2024
|
Charles River Labs (CRL) PT Raised to $300 at Evercore ISI
StreetInsider
|
Price Targets
Revenue
Forecast
Revenue Estimate
Charles River Laboratories International Inc
For the last 8 years the
compound annual growth rate for
Charles River Laboratories International Inc's revenue is
15%.
The projected
CAGR
for the next 4 years is
3%.
Operating Income
Forecast
Operating Income Estimate
Charles River Laboratories International Inc
For the last 8 years the
compound annual growth rate for
Charles River Laboratories International Inc's operating income is
14%.
The projected
CAGR
for the next 4 years is
11%.
Net Income
Forecast
Net Income Estimate
Charles River Laboratories International Inc
For the last 8 years the
compound annual growth rate for
Charles River Laboratories International Inc's net income is
16%.
The projected
CAGR
for the next 4 years is
9%.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is CRL's stock price target?
Price Target
220.21
USD
According to Wall Street analysts, the average 1-year price target for
CRL
is 220.21 USD
with a low forecast of 172.71 USD and a high forecast of 272.17 USD.
What is Charles River Laboratories International Inc's Revenue forecast?
Projected CAGR
3%
For the last 8 years the
compound annual growth rate for
Charles River Laboratories International Inc's revenue is
15%.
The projected
CAGR
for the next 4 years is
3%.
What is Charles River Laboratories International Inc's Operating Income forecast?
Projected CAGR
11%
For the last 8 years the
compound annual growth rate for
Charles River Laboratories International Inc's operating income is
14%.
The projected
CAGR
for the next 4 years is
11%.
What is Charles River Laboratories International Inc's Net Income forecast?
Projected CAGR
9%
For the last 8 years the
compound annual growth rate for
Charles River Laboratories International Inc's net income is
16%.
The projected
CAGR
for the next 4 years is
9%.
You don't have any saved screeners yet
